Breaking Down Barriers to Rare Disease Trials: A Q&A with Rachel Vanni, CEO of the Charlie Elenore Foundation
Understanding the complexities of the additional support needed for families caring for a child with a rare disease.
JPM 2025 Offered a Glimmer of Hope, Offered in Pink
This year's JPM Healthcare conference delivered a hopeful outlook for the future of biopharma for 2025.
Is Bluesky the End of the Social Media Marketing Megaphone ?
The next generation of social media is here. What does this new horizon mean for life science and pharma communication?
The Value of Nobel Prize-Winning AlphaFold for Rare Disease Research and Treatment
Of the approximately 20,000 proteins found in the human genome, only 7,074 of them had validated structures as of 2021. With AlphaFold, we now have predicted blueprints for the rem
To Create Valuable Therapies for Patients, Biopharma Leaders Must First Create Corporate Value. Communications Can Help.
Strategic communications are a valuable tool for enhancing corporate value, helping companies to shape perceptions and mitigate risks with carefully crafted messages. In this artic
ARM Really Turned up the Heat at the 2024 “Cell & Gene: Meeting on the Mesa”
Cell and gene therapies have made incredible progress in the last few years, and represent an actively growing field. Here, we highlight how improved patient access, a focus on ind
Centering the Patient Perspective in Healthcare Communications
Patient stories are key to effective healthcare communication. They can help stakeholders learn about and understand the significance of important advances that are shaping the fut
Exosomes: Small Messengers with Big Potential
The cells in our body constantly communicate with each other using microscopic membrane-bound packages called exosomes. Exosomes are potent carriers of information and capable of i
Sustainability Meets Science: Three Examples from the Next Frontier of Sustainable Life Science Innovation
Everyone recognizes the pressure to achieve sustainability, but it can be a tricky goal to chase. In industries like healthcare and biopharma, where patients can live or die based
